are γ-ketoaldehydes (IsoK) that rapidly react with lysines to form stable protein adducts. 
INTRODUCTION

Levuglandins and their regio-and stereo-isomers (isolevuglandins or isoketals)
are highly reactive γ-ketoaldehydes (IsoKs) formed by non-enzymatic rearrangement of prostaglandin H 2 and their free radical generated counterparts (H 2 -isoprostanes) (1) (2) (3) (4) (5) ( Figure 1 ). One feature of IsoKs that drew immediate interest was their extreme reactivity toward the lysyl residues of proteins, with reaction rates several orders of magnitude faster than the α, β-unsaturated aldehyde 4-hydroxynonenal, perhaps the most widely studied lipid peroxidation product (5, 6) . This increased reactivity derives from the facile formation of stable pyrrole adducts on primary amines. In the presence of oxygen, these pyrrole adducts convert over time into highly stable lactam adducts, as well as hydroxylactam adducts (5, 7) . Increased concentrations of IsoK protein adducts have been observed in vivo during a wide variety of conditions associated with inflammation and oxidative stress including atherosclerosis, end stage kidney disease, myocardial infarction, Alzheimer's Disease, glaucoma, hyperoxia, allergic inflammation, and experimental sepsis (8) (9) (10) (11) (12) (13) (14) .
Whether IsoK adducts contribute to pathogenesis of these diseases, or are simply bystander products resulting from the disease remains an active area of investigation.
Evidence supporting a potential role in pathogenesis comes from treatment of cultured cells with exogenous IsoK, which induces a variety of responses relevant to disease, The mechanism by which IsoK induces these effects has been presumed to be its adduction to cellular proteins, because of the high concentration of lysyl residues in cells.
However, these lysyl residues are not the only potential target of IsoK present in cells. In vitro, IsoK can form adducts with a variety of other primary amines including the aminophospholipid, phosphatidylethanolamine (PE) (20) (21) (22) . In phosphate buffer, the reaction rate of γ-ketoaldehydes to form pyrrole adducts with ethanolamine, the head group of the PE, is 4.4-fold faster than with lysine (20) . Oxidation of multilaminar vesicles containing PE or of isolated high density lipoprotein in vitro produces pyrrolized phospholipids (measured by reactivity with Ehrlich reagent), suggesting the robust modification of PE by pyrrole forming lipoxidation products under these conditions (23) .
Although the biological effects of IsoK modified PE have not been studied, modification of the ethanolamine headgroup of PE by IsoK is likely to dramatically affect the physical properties of PE as it converts the neutral PE to an acidic phospholipid and significantly increases headgroup bulk. PE modified by IsoK might also activate receptor-mediated signaling in a manner analogous to N-acyl-PE, which suppresses food intake via cFOS expression in neuropeptide Y neurons, and suppresses phagocytosis via Rac1 and Cdc42 in macrophages (24, 25) . We therefore sought to determine the extent to which IsoK adducts to PE compared to proteins and whether IsoK-PE could mediate L-α-Phosphatidylethanolamine (PE), transphosphatidylated from chicken egg phosphatidylcholine was purchased from Avanti Polar lipids (Alabaster, AL). According to the manufacturer and our LC/MS analysis, the major species of PE in this product is 1-palmitoyl-2-oleolyl-sn-glycerophosphotidylethanolamine (C34:1 PE). All solvents were HPLC grade and were purchased from EMD Biosciences. Streptomyces chromofuscus phospholipase D (PLD) was purchased from Enzo Life Sciences International (Plymouth Meeting, PA) and Proteinase K was purchased from Clontech (Mountain View, CA).
Human embryonic kidney (HEK293) cells were purchased from ATCC (Manassas, VA). 
Synthesis of modified PE and ethanolamine
Synthesis of IsoK-PE was performed by two methods. IsoK-PE was initially synthesized as described previously (21) . In brief, 1.25 μmol PE in CHCl 3 was dried down under nitrogen and resuspended in 1mL of a two phase mixture of ether/PBS (4:1).
125 nmol IsoK (0.1 molar equivalents) in 12.5 μL DMSO was added to the sample and incubated for 2 hours at 37°C. After incubation, the ether layer was dried off under nitrogen and 1mL chloroform/methanol (2:1) added. The resulting chloroform (lower) phase was transferred, dried under nitrogen, resuspended in 0.5 mL methanol/chloroform 
Mass spectrometry analysis
For limited mass scans of the products of the reaction between IsoK and the PE preparation, samples were injected into the ThermoFinnigan Quantum electrospray ionization triple quadrapole mass spectrometer operating in negative ion mode and scanning between m/z 600 and 1200. For collision induced disassociation spectrum, product ion scanning was performed on the m/z 1032.7 precursor ion, using argon gas in the collision cell. Collision energy was set at 50 eV. Similar analysis was performed on the PE preparation alone, with scanning performed at m/z 600 to m/z 1200, and a CID spectrum obtained for the precursor ion at m/z 716. using a XDB-C8 column at a flow rate of 500 μl/min starting at 100% Solvent A (water with 0.1% acetic acid) with a gradient ramp to 100% Solvent B (methanol with 0.1% acetic acid) at 3 minutes, and then holding at 100% Solvent B for 1 additional minute before returning to the starting conditions. The HPLC eluant was directly connected to the mass spectrometer operating in multiple reaction monitoring mode for m/z 378. To determine the concentration dependence of IsoK-PE induced HUVEC cytotoxicity, the concentration of IsoK, DMA, or vehicle treated PE were calculated from the amount of IsoK or DMA added to PE, respectively. Therefore, for each stated treated PE concentration, the total PE concentration (modified and unmodified PE) was equivalent for each type of treatment and was exactly ten fold higher than the stated treated PE concentration. IsoK-, DMA-, or vehicle-treated PE ( 0.1 to 30 μM final concentration)
were each added to six replicate wells of HUVEC. Untreated control wells were used to determine maximum viability. Cells were incubated with their respective treated PE for 22 h, and then 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) added to each well for an additional two hours, the culture media replaced with isopropanol and the extent of MTT conversion measured by the absorbance at 570 nm as previously described. Viability was normalized to the HBSS/A only treated cells.
To determine the amount of IsoK-PE that entered the cells during the incubation process to that amount of IsoK-PE formed when IsoK was directly incubated with cells , replicate plates of HUVEC cells were treated with 3 μM IsoK-PE for 2 hours, the incubation media removed, and IsoK-PE measured after PLD incubation as described for IsoK treated HUVEC cells.
RESULTS
Potential formation of non-protein adducts in IsoK treated cells
To identify significant cellular targets of IsoKs, a radiolabeled methyl ester 
Characterization of the reaction of IsoK with phosphatidylethanolamine
The amount of PE adduct formed in cells should depend both on the relative amount of PE and the reaction rate of PE versus other primary amines. The model γ-ketoaldehyde, 4-oxopentanal (OPA), reacts with ethanolamine 4.4 times faster than the reaction rate with N-acetyl lysine (20) . We determined the second order reaction rate of OPA and PE using similar methods as our previous study, except that we used a more lipophilic solvent system (1mM triethylammonium acetate/chloroform/ethanol 1:1:3 v/v/v) to maintain the solubility of the final product. In this lipophilic system, the To characterize the IsoK-PE adduct and to develop an analytical method to quantify these adducts, we reacted a commercial preparation of PE primarily containing 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (C34:1 PE) and lesser amounts of C34:2 PE, C36:1 PE, and C36:2 PE ( Figure 3A ) with a representative IsoK, 15-E 2 -IsoK ( Figure 3B ) and compared the resulting products ( Figure 3C ) by negative ion mass 
PE is a significant target of IsoK in cells
We then utilized this methodology to quantify the total amount of IsoK-PE 
IsoK-PE decreases the viability of endothelial cells.
To test whether IsoK-PE could induce similar effects as IsoK, we examined the (27) . Interestingly, the levels of PE adducts that they reported in healthy volunteers (3.4 ng/ml) are substantially higher than the levels of protein adduct than we have previously reported in plasma (0.56 ng/ml) (17) . The plasma ratio of PE to protein adducts in these two studies are very similar to the ratio of PE to protein adducts that we found in our cellular studies. Another publication during the revision period by Carrier et al showing that IsoK formed adducts on deoxycytidine (28) is consistent with our finding that IsoK also formed DNA adduct to a lesser extent then protein adducts.
The finding that PE adducts are formed to a greater extent than protein adducts raises the possibility that IsoK-PE is the active mediator of some of the biological effects of IsoK. Our finding that IsoK-PE alone is sufficient to induces cytotoxicity in HUVEC is consistent with the notion that IsoK induces cytotoxicity at least in part by forming www.jlr.org
